Surgical Specialties Corporation

Surgical Specialties Corporation, based in Pennsylvania, US, develops advanced surgical tools and solutions, focusing on enhancing outcomes in surgical procedures through innovative products such as sutures and hemostatic patches. Surgical Specialties Corporation specializes in producing surgical instruments and solutions. Founded in 1999 in Wyomissing, US, the company was acquired by Corza Health, Inc. in February 2021.

It has participated in a total of 3 deals since its inception. Surgical Specialties Corporation delivers high-performance surgical tools and solutions designed to enhance patient outcomes across various healthcare settings. Their primary offerings include innovative sutures, particularly the Quill brand, recognized for its self-closing technology that aids in reducing blood loss during surgical procedures. Additionally, the company provides a range of ophthalmic instruments and biologics aimed at advancing eye care, reflecting a focus on integrating state-of-the-art technology with the practical needs of healthcare providers.

The flagship product, TachoSil, is a hemostatic patch utilizing a closed-cell collagen matrix for effective blood clotting and sealing, ensuring their products meet the rigorous demands of healthcare professionals globally. Surgical Specialties Corporation generates revenue through direct sales of its surgical products and solutions to healthcare providers, primarily through a business-to-business model. The transactions typically involve significant agreements with hospitals and medical institutions, facilitating bulk purchases of products like Quill sutures and TachoSil hemostatic items. Pricing structures are determined based on volume and specific product types, with flagship items commanding premium pricing that reflects their advanced technology and clinical effectiveness.

Following the acquisition by Corza Health, Inc. in February 2021, Surgical Specialties Corporation plans to leverage recent funding to support the development of new products and expand its market presence. Specific new surgical tools are currently in the design phase, aimed at enhancing surgical efficiency. The company is targeting expansion into the European and Asian markets by 2023, with strategic partnerships to ensure successful entry into these regions.